Cheng Chi Wang
Technik-/Wissenschafts-/F&E-Leiter bei LIN BIOSCIENCE, INC.
Profil
Cheng Chi Wang is the founder of Belite Bio LLC, which was founded in 2016, where she holds the title of Chief Operating Officer.
She is currently the Head of Research & Development at Lin BioScience, Inc. since 2016.
Dr. Wang holds an MBA from the University of California San Diego and a doctorate from National Taiwan University.
Aktive Positionen von Cheng Chi Wang
| Unternehmen | Position | Beginn |
|---|---|---|
| LIN BIOSCIENCE, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2016 |
Belite Bio LLC
 Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The private company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | Gründer | 01.01.2016 |
Ausbildung von Cheng Chi Wang
| National Taiwan University | Doctorate Degree |
| University of California San Diego | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| LIN BIOSCIENCE, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The private company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | Health Technology |
